Stockscreener 앱 받기
3.88
8.49%
-0.36
시간 외 거래:
4.07
0.19
+4.90%
전일 마감가:
$4.24
열려 있는:
$4.17
하루 거래량:
120.42K
Relative Volume:
0.91
시가총액:
$244.14M
수익:
$34.16M
순이익/손실:
$-98.43M
주가수익비율:
-1.6581
EPS:
-2.34
순현금흐름:
$-119.33M
1주 성능:
-11.62%
1개월 성능:
+12.79%
6개월 성능:
-56.60%
1년 성능:
-35.23%
1일 변동 폭
$3.88
$4.3322
1주일 범위
$3.88
$4.454
52주 변동 폭
$2.9448
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
명칭
Foghorn Therapeutics Inc
전화
617-586-3100
주소
500 TECHNOLOGY SQUARE, CAMBRIDGE
FHTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
3.88 | 244.14M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-23 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-01-30 | 개시 | B. Riley Securities | Buy |
| 2024-09-03 | 개시 | Jefferies | Buy |
| 2024-08-19 | 개시 | Evercore ISI | Outperform |
| 2023-03-28 | 개시 | BofA Securities | Buy |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-22 | 개시 | H.C. Wainwright | Buy |
| 2020-11-17 | 개시 | Cowen | Outperform |
| 2020-11-17 | 개시 | Goldman | Buy |
| 2020-11-17 | 개시 | Morgan Stanley | Overweight |
| 2020-11-17 | 개시 | Wedbush | Outperform |
모두보기
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference - GlobeNewswire
Foghorn Therapeutics CEO to Present Gene Traffic Control Platform at Citizens Conference | FHTX Stock News - Stock Titan
Foghorn Therapeutics (FHTX) Expected to Announce Quarterly Earnings on Monday - Defense World
JPMorgan Chase & Co. Purchases 45,565 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics expands board with biotech veterans By Investing.com - Investing.com India
Foghorn Therapeutics expands board with biotech veterans - Investing.com
Foghorn Therapeutics Elects Neil Gallagher, M.D., Ph.D., and Stuart Duty to Board of Directors - Nasdaq
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire Inc.
Foghorn Therapeutics Presents New Preclinical Data on Selective - GuruFocus
Geode Capital Management LLC Boosts Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
FHTX Unveils Promising Preclinical Data at Cancer Research Confe - GuruFocus
Foghorn Therapeutics Presents Preclinical Data at AACR 2025 - TipRanks
Foghorn Therapeutics Presents New Preclinical Data on - GlobeNewswire
Breakthrough Cancer Drug FHD-909 Shows Synergy with Leading Treatments in Lung Cancer Studies - Stock Titan
Foghorn Therapeutics (NASDAQ:FHTX) Research Coverage Started at JMP Securities - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Earns Mkt Outperform Rating from Analysts at Citizens Jmp - Defense World
This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
JMP Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Market Outperform Recommendation - Nasdaq
Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Targ - GuruFocus
Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Target | FHTX Stock News - GuruFocus
Brokerages Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Price Target at $13.17 - Defense World
Foghorn Therapeutics to Host Virtual Investor Event to Review Pi - GuruFocus
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting | FHTX Stock News - GuruFocus
Foghorn Therapeutics to Host Virtual Investor Event to - GlobeNewswire
Major Pipeline Breakthrough: Foghorn's First-in-Class Cancer Drug Shows Promise in NSCLC Treatment - Stock Titan
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Bought by Wellington Management Group LLP - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Trading 4.1% Higher – Time to Buy? - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely - simplywall.st
(FHTX) Technical Data - news.stocktradersdaily.com
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Trend Tracker for (FHTX) - news.stocktradersdaily.com
Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients (NASDAQ:FHTX) - Seeking Alpha
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of “Buy” by Brokerages - The AM Reporter
Foghorn Therapeutics Announces New Preclinical Data for - GlobeNewswire
Breakthrough Cancer Drug FHD-909 Reveals Powerful Combination Potential Against Lung Cancer - Stock Titan
Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Target Price at $13.17 - Defense World
2,029,383 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Bought by Raymond James Financial Inc. - Defense World
Foghorn Therapeutics adjusts ATM offering to $100M By Investing.com - Investing.com Australia
Foghorn Therapeutics adjusts ATM offering to $100M - Investing.com
Research Analysts Offer Predictions for FHTX Q1 Earnings - The AM Reporter
What is B. Riley’s Forecast for FHTX Q1 Earnings? - Defense World
Foghorn Therapeutics Reports Progress and Financial Stability - TipRanks
Rhumbline Advisers Purchases 3,049 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics’ (FHTX) “Buy” Rating Reiterated at HC Wainwright - Defense World
Promising Advancements and Strategic Collaborations Position Foghorn Therapeutics as a Strong Buy - TipRanks
Promising Potential of Foghorn Therapeutics’ FHD-909 Drives Buy Rating Amid Strategic Advances - TipRanks
Foghorn Therapeutics Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Foghorn Therapeutics 2024 Net Loss Narrows, Revenue Declines -- Shares Slipping Late - Marketscreener.com
Foghorn Therapeutics Continues Enrollment in Phase 1 Trial of First-in-Class SMARCA2 Inhibitor FHD-909 for NSCLC and Reports Strong Financial Outlook - Nasdaq
Foghorn Therapeutics Inc (FHTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):